BACKGROUND/AIMS: Increasing levels of bacterial antibiotic resistance raise the need to assess the eradication efficiency of Helicobacter pylori. The aim of this study was to evaluate 7-year changes in efficacy of one-week first line and second line therapies in Helicobacter pylori eradication rates in Korea. METHODOLOGY: From 2001 to 2007, 4198 Helicobacter pylori-positive patients received first-line therapy (proton pump inhibitor, amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d.). Four hundred ninety patients received second-line therapy (proton pump inhibitor twelve hourly, metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., and bismuth 300 mg q.i.d.). A 13C-urea breath test was used to determine the eradication rate. RESULTS: The eradication rates of first-line therapy were 81.3%, 83.7%, 80.1%, 80.7%, 82.0%, 75.9%, and 77.5% from 2001 to 2007, with a decreasing trend (p < 0.01). The eradication rate of second-line therapy was 77.3%, 86.2%, 95.6%, 95.9%, 89.6%, 83.2%, and 86.4% from 2001 to 2007 without decreasing trend (p = 0.26). CONCLUSIONS: The eradication rate of first-line therapy has decreased in the last 7 years while that of second-line therapy has remained the same. A new strategy is required to improve the first-line therapy for Helicobacter pylori eradication in Korea.
BACKGROUND/AIMS: Increasing levels of bacterial antibiotic resistance raise the need to assess the eradication efficiency of Helicobacter pylori. The aim of this study was to evaluate 7-year changes in efficacy of one-week first line and second line therapies in Helicobacter pylori eradication rates in Korea. METHODOLOGY: From 2001 to 2007, 4198 Helicobacter pylori-positive patients received first-line therapy (proton pump inhibitor, amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d.). Four hundred ninety patients received second-line therapy (proton pump inhibitor twelve hourly, metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., and bismuth 300 mg q.i.d.). A 13C-urea breath test was used to determine the eradication rate. RESULTS: The eradication rates of first-line therapy were 81.3%, 83.7%, 80.1%, 80.7%, 82.0%, 75.9%, and 77.5% from 2001 to 2007, with a decreasing trend (p < 0.01). The eradication rate of second-line therapy was 77.3%, 86.2%, 95.6%, 95.9%, 89.6%, 83.2%, and 86.4% from 2001 to 2007 without decreasing trend (p = 0.26). CONCLUSIONS: The eradication rate of first-line therapy has decreased in the last 7 years while that of second-line therapy has remained the same. A new strategy is required to improve the first-line therapy for Helicobacter pylori eradication in Korea.
Authors: Jae Jin Hwang; Dong Ho Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim Journal: World J Gastroenterol Date: 2015-09-21 Impact factor: 5.742
Authors: Hyun Jeong Lee; Jin Il Kim; Jin Soo Lee; Eun Jung Jun; Jung-Hwan Oh; Dae Young Cheung; Woo Chul Chung; Byung-Wook Kim; Sung Soo Kim Journal: World J Gastroenterol Date: 2015-01-07 Impact factor: 5.742
Authors: Sang-Pil Yun; Han Gyung Seon; Chang Soo Ok; Kwang Ho Yoo; Min Kyung Kang; Won Hee Kim; Chang Il Kwon; Kwang Hyun Ko; Seong Gyu Hwang; Pil Won Park; Sung Pyo Hong Journal: Gut Liver Date: 2012-10-18 Impact factor: 4.519
Authors: Chang Seok Bang; Yeon Soo Kim; Sang Hyun Park; Jin Bong Kim; Gwang Ho Baik; Ki Tae Suk; Jai Hoon Yoon; Dong Joon Kim Journal: Gut Liver Date: 2015-05-23 Impact factor: 4.519